2 nd PROCART Forum. October 9th, 2012

Transcription

1 2 nd PROCART Forum October 9th, 2012

2 The main investments in cancer research 2012 research Spending 120 M Including INCa, Aviesan cancer, Ministry of Health

3 cancer biology, cancer sciences, genomics Activities and programmes conducted in Investigator-driven research programmes in Cancer Biology and Sciences (Funding INCa) Research programmes in cancer and Physics, Maths, Engineering (Funding Aviesan cancer) Research programmes in Systems Biology (Funding Aviesan cancer) Support to technological platforms (Funding Aviesan cancer) Support and coordination of biobanks (Funding Ministry of Health, coordination INCa) ( 5 M/y) International programme ICGC (Funding INCa and Aviesan cancer) Multi-year funding 2011 Multi-year funding M 15.9 M 2.7 M 4 M NA 2 M 2 M 2.5 M 2.5 M

4 Cancer Biology and Sciences The largest research programme at INCa in number of submitted projects and funding

5 Clinical research Activities and programmes Clinical research programmes (PHRC STIC) 21 M 2M 21 M 0.5 M NA 0.5 M (Funding Ministry of Health) Network of 16 early phase clinical trials centres: CLIP2 (Cofunding INCa ARC (Multi year funding 9M/4 y ) PPP: innovative molecules Designation of cooperative inter-groups (Funding INCa) Network of clinical research nurses 3M 3M Network of data processing centres 1M 1M (Funding Ministry of Health) (Funding Ministry of Health) Cancer clinical trial registry

6 Network of 16 early phase clinical trials centres: CLIP2

7 Translational research programmes DISTRIBUTION OF THE BUDGET ALLOCATED TO THE TRANSLATIONAL RESEARCH PROGRAMME TRENDS IN SELECTION FOR THE TRANSLATIONAL RESEARCH PROGRAMME First evaluation of results scheduled for 2013

8 Development of spontaneous tumour models Research programmes In collaboration with Aviesan cancer To increase collaboration between vets, clinicians and biomedical researchers Promote development and translation of research tools 6 projects in total, 1.95 M Objectives Identify alternative pre-clinical animal models; spontaneous tumors Spontaneous tumours in dogs for antibody therapeutics Data of such quality that it can be translated to human medicine Mobilisation of research communities led to the creation of large EU consortia Application ongoing for EU funding

9 Research organisation dedicated to translational / integrated research The SIRIC programme Integration of medical, scientific and societal research Joint and collaborative programs 8 SIRIC, 59M (5 years) Ongoing networking of the SIRIC

10 Social sciences, epidemiology, public health Activities and programmes conducted in Multi-year funding 2011 Multi-year funding 2012 Investigator-driven research programmes (Funding INCa) 4.5 M 3.8 M Health intervention research (Funding INCa) 1.5 M 2.1 M Employment and cancer (Funding INCa and ARC) NA Support to Cohorts and collaborative call (IReSP) 0.48 M 1M 1.86 M Calls for clinico-biological databases (Funding INCa) 2.3 M Pending Collaborative calls in environmental risks and cancer NA 2.4 M (Funding Aviesan cancer) Collaborative calls (Anses) in Work Health Environment (Funding Aviesan cancer) 1.26 M 1M anticipated

11 Personalised Medicine for an equal access to cancer treatment in France S t C lo u d / P a r is ( 2 ) : A P - H P, C u r i e V e r sa illes V illeju if 28 regional molecular genetics centres Perform molecular testing for all patients Whatever the healthcare institution status (public hospitals, private hospitals ) L i lle C aen Perform high quality tests Leukemia, solid tumours R ouen R e im s N a ncy B re s t R ennes A n g e rs T o u rs N a n te s D i jo n S tra s b o u rg / M u lh o u s e / C o lm a r B esa nçon P o itie r s L im o g e s C le r m o n t L y o n F e r r a n d S t E tie n n e G r e n o b le B o rd e a u x Toulouse N ice M o n tp e llie r / N îm e s M a r s e ill e

12 Int. cancer genomics consortium: ICGC Int. Epigenome Consortium: IHEC

13 ICGC: Liver Cancer genome programme Guichard et al. Nature Genetics, 2012

14 Targeted therapies with sufficient preclinical and clinical data (level 1) Activation of AKT/mTor pathway (20 %) Activation of ras/raf/map kinase pathway (9 %) Cytokine and growth factor receptors (7 %) PIK3CA mutations (1 %) TSC1 and TSC2 mutations (7 %) PTEN HD (2 %) Activation without known mutation (10 %) BRAF mutation (1 %) mtor inhibitor (everolimus, sirolimus) BRAF V600 inhibitor (vemurafenib) FGF19 amplification (1 %) FGFR inhibitor (pazopanib) EGFR overexpression (1%) Antibody anti-egfr HER2neu overexpression (1%) Private mutations (2 %) Targeted therapy SUFU mutation (1 %) MGMT HD (1%) (cetuximab) Antibody anti-her2 (trastuzumab) Inhibitor of sonic hedgehog (vismodegib) Oral alkylating agent (temozolomid)

15 Putative targeted therapies: ongoing pre-clinical analyses (level 2) Targeted therapy Activation of NFE2L2/KEAP1 pathway (20 %) Activation of ras/raf/map kinase pathway (9 %) Cytokine and growth factor receptors (7 %) NFE2L2 mutation (5 %) KEAP1 mutation (3 %) Activation without known mutation (12 %) RPS6KA3 mutation (8 %) IL6ST mutation (2 %) HSP90 inhibitor (17AAG and 17-DMAG) MEK 1/2 inhibitor (selumitinib) JAK1/JAK2 inhibitor (ruxolitinib)